ReviewStem cell research & therapy2026
Improving stem cell-derived extracellular vesicles for better tendon and tendon-to-bone junction regeneration: strategies and future directions.
Review in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Chronic tendinopathy is a debilitating tendon overuse disorder characterized by localized tenderness, swelling, and pain, significantly impairing physical function. It is particularly common among the overuse and aging populations. Traditional treatment options, including conservative therapies and surgical interventions, often yield limited success. Recent studies indicate that extracellular vesicles (EV) derived from stem cells provide a promising therapeutic avenue for healing of tendon and tendon-to-bone junction (TBJ) injuries associated with chronic tendinopathy. Their unique properties, such as higher cargo stability and the ability to serve as carriers for targeted drug delivery, position them as ideal candidates for tendinopathy treatment. However, the low yield of EVs presents challenges for clinical applications. This review systematically review various strategies to enhance EV yield and function, including preconditioning stem cells through biophysical, biological, or chemical means; genetic engineering of stem cells; in vitro loading of proteins or drugs and surface modification of EVs; and modifying the stem cell culture environment, particularly through three-dimensional (3D) culture techniques. Emphasis is placed on scaffold-free methods, scaffold-based methods, 3D printing, spinner flasks, and bioreactors, which can potentially improve EV yield and functions for tendon and TBJ regeneration. The review also summarizes relevant preclinical data and explores the molecular mechanisms underlying enhanced EV yield and functions, as well as the mechanisms of EVs on tendon and TBJ repair. Future research directions include investigating various EV enhancement strategies in models of degenerative tendon injury, studying the underlying molecular mechanisms, establishing cost-effective methods for scalable EV production, optimizing EV treatment protocols for clinical translation, and exploring combination strategies to enhance therapeutic EV production and function.
Indexed as
Identifiers
42458649What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.